Compare Stocks: FGEN, TNYA, OTLK, and INDP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
INDP Indaptus Therapeutics	$1.22 +5.2%	$1.88	$0.92 ▼ $8.57	$162.55M	1.17	511,027 shs	133,112 shs
OTLK Oncobiologics	$0.67 +2.7%	$1.11	$0.16 ▼ $2.54	$162.26M	0.74	13.39 million shs	6.36 million shs
TNYA Tenaya Therapeutics	$0.68 -1.7%	$0.76	$0.53 ▼ $2.35	$153.19M	2.77	3.51 million shs	1.20 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-18.31%
INDP Indaptus Therapeutics	-0.85%	0.00%	-14.71%	-68.31%	-78.52%
OTLK Oncobiologics	+3.62%	+1.23%	-32.41%	-16.44%	-27.08%
TNYA Tenaya Therapeutics	-0.57%	+0.01%	-6.24%	-4.50%	-41.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$9.77 +8.3%	$9.21	$4.85 ▼ $12.60	$39.57M	0.77	40,794 shs	31,125 shs
INDP Indaptus Therapeutics	$1.22 +5.2%	$1.88	$0.92 ▼ $8.57	$162.55M	1.17	511,027 shs	133,112 shs
OTLK Oncobiologics	$0.67 +2.7%	$1.11	$0.16 ▼ $2.54	$162.26M	0.74	13.39 million shs	6.36 million shs
TNYA Tenaya Therapeutics	$0.68 -1.7%	$0.76	$0.53 ▼ $2.35	$153.19M	2.77	3.51 million shs	1.20 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	0.00%	0.00%	0.00%	0.00%	-18.31%
INDP Indaptus Therapeutics	-0.85%	0.00%	-14.71%	-68.31%	-78.52%
OTLK Oncobiologics	+3.62%	+1.23%	-32.41%	-16.44%	-27.08%
TNYA Tenaya Therapeutics	-0.57%	+0.01%	-6.24%	-4.50%	-41.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FGEN FibroGen	2.00	Hold	$43.00	340.12% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
OTLK Oncobiologics	2.20	Hold	$5.20	673.81% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	483.09% Upside

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, OTLK, and INDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	OTLK Oncobiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$1.60
7/27/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $10.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FGEN FibroGen	$29.62M	1.34	N/A	N/A	($50.89) per share	-0.19
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
OTLK Oncobiologics	$1.35M	121.18	N/A	N/A	($0.04) per share	-16.80
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FGEN FibroGen	-$47.58M	$53.48	0.18	N/A	N/A	2,598.55%	N/A	-26.27%	N/A
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest FGEN, TNYA, OTLK, and INDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FGEN FibroGen	N/A	3.71	3.60
INDP Indaptus Therapeutics	N/A	19.49	19.49
OTLK Oncobiologics	N/A	0.81	0.63
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FGEN FibroGen	72.71%
INDP Indaptus Therapeutics	7.06%
OTLK Oncobiologics	11.20%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
FGEN FibroGen	3.07%
INDP Indaptus Therapeutics	9.94%
OTLK Oncobiologics	1.80%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FGEN FibroGen	570	4.05 million	3.92 million	Optionable
INDP Indaptus Therapeutics	6	133.24 million	120.00 million	Not Optionable
OTLK Oncobiologics	20	243.45 million	239.07 million	Optionable
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable

FGEN, TNYA, OTLK, and INDP Headlines

Recent News About These Companies

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3 at 4:30 PM | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Rating Lowered by Wall Street Zen

August 29, 2026 | americanbankingnews.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

August 18, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

August 17, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA

August 10, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings

August 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Q3 Earnings Forecast for TNYA Issued By HC Wainwright

August 7, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results

August 5, 2026 | marketbeat.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday

August 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FGEN, TNYA, OTLK, and INDP Company Descriptions

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Indaptus Therapeutics NASDAQ:INDP

$1.22 +0.06 (+5.17%)

As of 04:00 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Oncobiologics NASDAQ:OTLK

$0.67 +0.02 (+2.70%)

As of 04:00 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Tenaya Therapeutics NASDAQ:TNYA

$0.68 -0.01 (-1.74%)

As of 04:00 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, OTLK, and INDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, TNYA, OTLK, and INDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, TNYA, OTLK, and INDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FGEN, TNYA, OTLK, and INDP Company Descriptions

FibroGen NASDAQ:FGEN

Indaptus Therapeutics NASDAQ:INDP

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FGEN, TNYA, OTLK, and INDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FGEN, TNYA, OTLK, and INDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FGEN, TNYA, OTLK, and INDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FGEN, TNYA, OTLK, and INDP Company Descriptions

FibroGen NASDAQ:FGEN

Indaptus Therapeutics NASDAQ:INDP

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools